EUVIMEDOtkrijte EUVIMED
CrossrefInformacijska kartica

Controlled Hypothermic Storage and Time‐Shifting in Lung Transplantation: A Single‐Center Study

Andrew Keogan, Theodore Lin, Mark Shacker, Lucia Chang, Lucas Wang, Rajat Walia, Ross M. Bremner, Jasmine Huang, Nathan Zwintscher, Michael A. Smith, Lara W. Schaheen

Clinical Transplantation · 2026-11 · 40 (11)

DOI: 10.1111/ctr.70684 ↗
SažetakBibliografski podaci

Sažetak

ABSTRACT Purpose This study compared lung transplant outcomes between cases using controlled hypothermic storage (CHS) donor lung transport with ischemic times > 6 h and those using cold static storage (CSS) transport with ischemic times < 6 h. Methods We retrospectively reviewed lung transplantations performed at our center from September 15, 2014 to March 29, 2025, excluding ex vivo lung perfusion, single‐lung, redo, and multi‐organ cases. Perioperative outcomes were assessed using univariate, multivariable, survival, and propensity‐matched analyses. Results Among 770 recipients, 87 (11.3%) and 683 (88.7%) received lungs preserved using CHS and CSS, respectively. In the CHS group, ischemic times were significantly longer (median, 11.0 vs. 4.3 h, p < 0.001), and transport distances were greater (median, 750 vs. 219 nautical miles, p < 0.001). CHS was associated with higher rates of daytime transplantation (79% vs. 51%, p < 0.001) and delayed chest closure (22% vs. 13%, p = 0.023). Primary graft dysfunction grade 3 (PGD3) at 72 h was lower in the CHS group (13% vs. 26%, p = 0.019), and CHS was independently associated with a lower risk of PGD3 on multivariable analysis (aOR 0.38, 95% CI 0.17–0.83, p = 0.016). In a propensity‐matched analysis, PGD3 at 72 h was lower in the CHS group, but the difference did not reach statistical significance (12% vs. 26%, p = 0.059). Kaplan–Meier analysis demonstrated similar survival between groups ( p = 0.53). Conclusion CHS enables the safe extension of ischemic time beyond conventional limits, facilitating broader geographic access and a shift toward increased daytime transplantation. Short‐term outcomes were comparable to those of CSS, with a lower incidence of PDG3.

Znanje koje odgovara vašem radu.

Od besplatnog početka i osobnog pretraživanja literature do potpunog paketa Research Suite.

Prikaži tarife →

Jesu li uključeni svi cjeloviti tekstovi izdavača?

Ne. Bibliografski zapisi, sažeci i cjeloviti tekstovi različiti su sadržaji. Hoće li cjeloviti tekst biti dostupan ovisi o izvoru, Open Accessu i vašim postojećim licencama. Tarifa EUVIMED ne zamjenjuje dodatna izdavačka prava.

Prikaži tarife →